Oncobiologics (NASDAQ:OTLK) Director Purchases $100,167.90 in Stock

Oncobiologics, Inc. (NASDAQ:OTLK) Director Faisal Ghiath Sukhtian bought 95,398 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was purchased at an average price of $1.05 per share, for a total transaction of $100,167.90. Following the completion of the acquisition, the director owned 220,972 shares in the company, valued at $232,020.60. This represents a 75.97% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Oncobiologics Stock Up 10.6%

OTLK stock traded up $0.10 during midday trading on Wednesday, reaching $1.00. 27,987,638 shares of the company’s stock traded hands, compared to its average volume of 12,368,565. The company has a market cap of $148.59 million, a price-to-earnings ratio of -0.85 and a beta of 0.77. The firm’s fifty day moving average price is $1.21 and its 200-day moving average price is $0.66. Oncobiologics, Inc. has a 52 week low of $0.16 and a 52 week high of $3.39.

Oncobiologics (NASDAQ:OTLK) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The business had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $4.39 million. Analysts forecast that Oncobiologics, Inc. will post -0.48 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Russell Investments Group Ltd. boosted its holdings in Oncobiologics by 865.2% during the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after purchasing an additional 21,941 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Oncobiologics by 74.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock valued at $126,000 after buying an additional 44,063 shares during the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of Oncobiologics by 42.7% during the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock worth $103,000 after buying an additional 25,351 shares in the last quarter. 11.20% of the stock is owned by institutional investors.

Key Headlines Impacting Oncobiologics

Here are the key news stories impacting Oncobiologics this week:

• Positive Sentiment: BTIG upgraded OTLK to Buy, providing a stronger bullish signal and potentially supporting the stock’s recent increase. BTIG Research Upgrades Oncobiologics to Buy
• Positive Sentiment: HC Wainwright raised its FY2027 EPS forecast sharply to a loss of $0.03 per share from a loss of $0.21. It also improved estimates for the third quarter of 2026 and each quarter of 2027, suggesting expectations for reduced cash burn and a path toward profitability. The firm projects positive EPS of $0.09 in FY2028, $0.15 in FY2029 and $0.32 in FY2030. HC Wainwright earnings estimates for Oncobiologics
• Neutral Sentiment: HC Wainwright maintained its Neutral rating and $1.60 price target. The target implies potential upside based on the background price, but the unchanged rating indicates that the analyst views the risk-reward profile as balanced rather than decisively bullish.
• Negative Sentiment: HC Wainwright lowered its FY2026 EPS forecast to a loss of $0.47 from a loss of $0.42, highlighting continued near-term losses. The analyst still expects losses through FY2027, although those losses are narrowing.
• Negative Sentiment: An analysis of LYTENAVA’s FDA and European approvals cautioned that OTLK faces significant cash constraints and may need strategic funding or a partnership to finance the U.S. launch. Although LYTENAVA addresses the large wet age-related macular degeneration market, competition and uncertain market adoption could limit the commercial benefit. Caution on LYTENAVA FDA approval and cash needs

Analyst Upgrades and Downgrades

OTLK has been the topic of several recent research reports. Wall Street Zen cut shares of Oncobiologics from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Weiss Ratings raised Oncobiologics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, June 24th. BTIG Research raised Oncobiologics from a “neutral” rating to a “buy” rating and set a $4.00 price objective for the company in a research note on Monday. HC Wainwright raised their target price on Oncobiologics from $0.50 to $1.60 and gave the company a “neutral” rating in a report on Monday. Finally, Ascendiant Capital Markets lifted their target price on Oncobiologics from $6.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, June 11th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $4.65.

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.